Microarray patches: scratching the surface of vaccine delivery
Introduction Microneedles are emerging as a promising technology for vaccine delivery, with numerous advantages over traditional needle and syringe methods. Preclinical studies have demonstrated the effectiveness of MAPs in inducing robust immune responses over traditional needle and syringe methods...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2023.2270598 |
| _version_ | 1797633707556732928 |
|---|---|
| author | Jovin J. Y. Choo Christopher L. D. McMillan Paul R. Young David A. Muller |
| author_facet | Jovin J. Y. Choo Christopher L. D. McMillan Paul R. Young David A. Muller |
| author_sort | Jovin J. Y. Choo |
| collection | DOAJ |
| description | Introduction Microneedles are emerging as a promising technology for vaccine delivery, with numerous advantages over traditional needle and syringe methods. Preclinical studies have demonstrated the effectiveness of MAPs in inducing robust immune responses over traditional needle and syringe methods, with extensive studies using vaccines targeted against different pathogens in various animal models. Critically, the clinical trials have demonstrated safety, immunogenicity and patient acceptance for MAP-based vaccines against influenza, measles and rubella, and SARS-CoV-2. Areas covered This review provides a comprehensive overview of the different types of microarray patches (MAPs) and analyses of their applications in preclinical and clinical vaccine delivery settings. This review also covers additional considerations for microneedle-based vaccination, including adjuvants that are compatible with MAPs, patient safety and factors for global vaccination campaigns. Expert opinion MAP vaccine delivery can potentially be a game-changer for vaccine distribution and coverage in both high-income and low or middle-income countries. For MAPs to reach this full potential, many critical hurdles must be overcome, such as large-scale production, regulatory compliance, and adoption by global health authorities. However, given the considerable strides made in recent years by MAP developers, it may be possible to see the first MAP-based vaccines in use within the next 5 years. |
| first_indexed | 2024-03-11T11:58:37Z |
| format | Article |
| id | doaj.art-4ecb781fea1a40208370ae0a080e5da2 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T11:58:37Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-4ecb781fea1a40208370ae0a080e5da22023-11-08T11:44:54ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952023-12-010010.1080/14760584.2023.22705982270598Microarray patches: scratching the surface of vaccine deliveryJovin J. Y. Choo0Christopher L. D. McMillan1Paul R. Young2David A. Muller3The University of QueenslandThe University of QueenslandThe University of QueenslandThe University of QueenslandIntroduction Microneedles are emerging as a promising technology for vaccine delivery, with numerous advantages over traditional needle and syringe methods. Preclinical studies have demonstrated the effectiveness of MAPs in inducing robust immune responses over traditional needle and syringe methods, with extensive studies using vaccines targeted against different pathogens in various animal models. Critically, the clinical trials have demonstrated safety, immunogenicity and patient acceptance for MAP-based vaccines against influenza, measles and rubella, and SARS-CoV-2. Areas covered This review provides a comprehensive overview of the different types of microarray patches (MAPs) and analyses of their applications in preclinical and clinical vaccine delivery settings. This review also covers additional considerations for microneedle-based vaccination, including adjuvants that are compatible with MAPs, patient safety and factors for global vaccination campaigns. Expert opinion MAP vaccine delivery can potentially be a game-changer for vaccine distribution and coverage in both high-income and low or middle-income countries. For MAPs to reach this full potential, many critical hurdles must be overcome, such as large-scale production, regulatory compliance, and adoption by global health authorities. However, given the considerable strides made in recent years by MAP developers, it may be possible to see the first MAP-based vaccines in use within the next 5 years.http://dx.doi.org/10.1080/14760584.2023.2270598microneedlesmicroarray patchskin vaccinationvaccine delivery |
| spellingShingle | Jovin J. Y. Choo Christopher L. D. McMillan Paul R. Young David A. Muller Microarray patches: scratching the surface of vaccine delivery Expert Review of Vaccines microneedles microarray patch skin vaccination vaccine delivery |
| title | Microarray patches: scratching the surface of vaccine delivery |
| title_full | Microarray patches: scratching the surface of vaccine delivery |
| title_fullStr | Microarray patches: scratching the surface of vaccine delivery |
| title_full_unstemmed | Microarray patches: scratching the surface of vaccine delivery |
| title_short | Microarray patches: scratching the surface of vaccine delivery |
| title_sort | microarray patches scratching the surface of vaccine delivery |
| topic | microneedles microarray patch skin vaccination vaccine delivery |
| url | http://dx.doi.org/10.1080/14760584.2023.2270598 |
| work_keys_str_mv | AT jovinjychoo microarraypatchesscratchingthesurfaceofvaccinedelivery AT christopherldmcmillan microarraypatchesscratchingthesurfaceofvaccinedelivery AT paulryoung microarraypatchesscratchingthesurfaceofvaccinedelivery AT davidamuller microarraypatchesscratchingthesurfaceofvaccinedelivery |